Back to top

messenger-rna: Archive

Zacks Equity Research

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.

MRNANegative Net Change ABUSNegative Net Change ROIVPositive Net Change